LL-37 as a therapeutic target for late stage prostate cancer.
about
The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer DrugsThe bone marrow-expressed antimicrobial cationic peptide LL-37 enhances the responsiveness of hematopoietic stem progenitor cells to an SDF-1 gradient and accelerates their engraftment after transplantationAntimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1.Tumor-produced versican V1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression in vitro.Proteins and an inflammatory network expressed in colon tumors.Prioritization of cancer marker candidates based on the immunohistochemistry staining images deposited in the human protein atlas.Cathelicidin, an antimicrobial peptide produced by macrophages, promotes colon cancer by activating the Wnt/β-catenin pathwayMagnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cellsmiR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway.The Role of Cathelicidin LL-37 in Cancer Development.Antimicrobial peptide LL-37 promotes the proliferation and invasion of skin squamous cell carcinoma by upregulating DNA-binding protein A.Activation of TRPV2 and BKCa channels by the LL-37 enantiomers stimulates calcium entry and migration of cancer cells.Calcitriol stimulates gene expression of cathelicidin antimicrobial peptide in breast cancer cells with different phenotype.Antimicrobial peptide LL-37 promotes YB-1 expression, and the viability, migration and invasion of malignant melanoma cells.Defensins and LL-37: a review of function in the gingival epitheliumProstate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages.Expression of the antimicrobial peptide cathelicidin in myeloid cells is required for lung tumor growth.Exogenous murine antimicrobial peptide CRAMP significantly exacerbates Ovalbumin-induced airway inflammation but ameliorates oxazolone-induced intestinal colitis in BALB/c mice.Expression of Antimicrobial Peptides by Uveal and Cutaneous Melanoma Cells and Investigation of Their Role in Tumor Cell Migration and Vasculogenic Mimicry.A deficiency in cathelicidin reduces lung tumor growth in NNK/NTHi-induced A/J miceLow-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes
P2860
Q26801532-4B1C92FF-0C67-4BC7-A5B4-DAD70F789B48Q30424789-F79517CE-351A-4A28-84FF-C4999981D2DAQ33846843-BAFCD58C-986C-451F-9B20-E5FCE50CE069Q34592889-495D260C-1A67-4DDF-B3B2-065F2A16BA55Q34958339-9C01B24D-6217-4EB8-B75C-BA67223C92FDQ35058538-409624FF-3B67-4B7D-853C-CA0262458DA3Q35550144-53DD2994-BE53-4B52-A8F0-0B8FD555CA5DQ35703756-AFD3763B-C0E5-4618-B5B0-53C1E1205563Q36243109-305F8506-191C-48F1-9AB8-4AB66767D6DAQ36465085-52EEEFAA-368C-4FC0-B7E6-DADAE731BF6EQ37204334-7CFBDAFC-0162-4A7A-94F2-C1B7C3FA9974Q37269132-3F0EC6BF-5D4A-4AA3-A18A-D456BFD04C23Q37406121-2269703E-0A99-4E71-B8CE-22A261B9D5C7Q37707536-C5175F6E-60BB-49C3-9B34-74FBDFC6D50DQ38127778-4235236C-F8CF-437B-BDAB-F2AA245E82E6Q38795562-A5494804-780F-44DD-B55C-6843D65755E1Q39133003-1E101B88-163A-40B2-8085-E32E883D5E01Q47429893-6A0C3217-581E-4CF5-A82D-2F7111156722Q47986044-62F9C598-C147-46EB-92F8-8C1A44058432Q57177536-BA3CCA87-1E8F-45DE-BE35-E522CF4E5C02Q58759873-7F4F3C17-B602-4103-A25D-91A3EBEC60BA
P2860
LL-37 as a therapeutic target for late stage prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
LL-37 as a therapeutic target for late stage prostate cancer.
@ast
LL-37 as a therapeutic target for late stage prostate cancer.
@en
LL-37 as a therapeutic target for late stage prostate cancer.
@nl
type
label
LL-37 as a therapeutic target for late stage prostate cancer.
@ast
LL-37 as a therapeutic target for late stage prostate cancer.
@en
LL-37 as a therapeutic target for late stage prostate cancer.
@nl
prefLabel
LL-37 as a therapeutic target for late stage prostate cancer.
@ast
LL-37 as a therapeutic target for late stage prostate cancer.
@en
LL-37 as a therapeutic target for late stage prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
LL-37 as a therapeutic target for late stage prostate cancer.
@en
P2093
Anandi Sawant
Diptiman Chanda
Jonathan A Hensel
Sanjay Kumar
Selvarangan Ponnazhagan
William E Grizzle
P2860
P304
P356
10.1002/PROS.21282
P577
2010-10-18T00:00:00Z